Restricted accessResearch articleFirst published online 2014-10
Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide
Low prevalence of detectable cardiac troponin in healthy people and low-risk patients previously curtailed its use. With a new high-sensitive cardiac troponin assay (hs-cTnT), concentrations below conventional detection may have prognostic value, notably in combination with N-terminal pro-B-type natriuretic peptide (NT-pro-BNP).
Methods and results
Biomarker concentrations were determined from serum obtained at enrolment in the CLARICOR trial involving 4197 patients with stable coronary artery disease (CAD) followed for 2.6 years. Serum hs-cTnT was detectable (above 3 ng/l) in 78% and above the conventional 99th percentile (13.5 ng/l) in 23%. Across all levels of hs-cTnT there was a graded increase in the risk of cardiovascular death after adjustment for known prognostic indicators: hazard ratio (HR) per unit increase in the natural logarithm of the hs-cTnT level, 1.49; 95% confidence interval (CI), 1.23–1.81; similarly for all-cause mortality (HR 1.48, 95% CI 1.29–1.70) and myocardial infarction (HR 1.37, 95% CI 1.13–1.67). Increasing values of hs-cTnT were associated with increased mortality across all values of NT-pro-BNP, but this was particularly prominent when NT-pro-BNP >400 ng/l.
Conclusions
In patients with stable CAD, any detectable hs-cTnT level is significantly associated with all-cause mortality, cardiovascular death, and myocardial infarction after adjustment for traditional risk factors and NT-pro-BNP. Excess mortality is particularly pronounced in patients with NT-pro-BNP >400 ng/l.
HickmanPEPotterJMAroneyC. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta2010; 411: 318–323.
2.
AntmanEMTanasijevicMJThompsonB. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med1996; 335: 1342–1349.
3.
HammCWRavkildeJGerhardtW. The prognostic value of serum troponin T in unstable angina. N Engl J Med1992; 327: 146–150.
4.
LindahlBTossHSiegbahnA. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med2000; 343: 1139–1147.
5.
OhmanEMArmstrongPWChristensonRH. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med1996; 335: 1333–1341.
6.
deFilippiCWassermanSRosanioS. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA2003; 290: 353–359.
7.
EggersKMLindLAhlstromH. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J2008; 29: 2252–2258.
8.
SatoYYamadaTTaniguchiR. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation2001; 103: 369–374.
9.
WallaceTWAbdullahSMDraznerMH. Prevalence and determinants of troponin T elevation in the general population. Circulation2006; 113: 1958–1965.
10.
ZetheliusBJohnstonNVengeP. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation2006; 113: 1071–1078.
11.
de LemosJADraznerMHOmlandT. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA2010; 304: 2503–2512.
12.
KellerTZellerTPeetzD. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med2009; 361: 868–877.
13.
LankeitMFriesenDAschoffJ. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J2010; 31: 1836–1844.
14.
LatiniRMassonSAnandIS. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation2007; 116: 1242–1249.
15.
OmlandTde LemosJASabatineMS. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med2009; 361: 2538–2547.
16.
ReichlinTHochholzerWBassettiS. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med2009; 361: 858–867.
17.
WieseSBreyerTDraguA. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation2000; 102: 3074–3079.
18.
BursiFWestonSARedfieldMM. Systolic and diastolic heart failure in the community. JAMA2006; 296: 2209–2216.
19.
CowieMRStruthersADWoodDA. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet1997; 350: 1349–1353.
20.
DavisMEspinerERichardsG. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet1994; 343: 440–444.
21.
Bibbins-DomingoKAnsariMSchillerNB. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation2003; 108: 2987–2992.
HamaNItohHShirakamiG. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation1995; 92: 1558–1564.
25.
JamesSKLindbackJTillyJ. Troponin‐T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol2006; 48: 1146–1154.
26.
DanielsLBLaughlinGACloptonP. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol2008; 52: 450–459.
27.
KaptogeSDiAELoweG. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet2010; 375: 132–140.
28.
SinningJMBickelCMessowCM. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J2006; 27: 2962–2968.
29.
GuptaSLeathamEWCarringtonD. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation1997; 96: 404–407.
30.
JespersenCMAls-NielsenBDamgaardM. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ2006; 332: 22–27.
31.
KjollerEHildenJWinkelP. Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. J Clin Epidemiol2012; 65: 444–453.
32.
GluudCAls-NielsenBDamgaardM. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008; 111: 280–287.
33.
GiannitsisEBeckerMKurzK. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem2010; 56: 642–650.
34.
DicksteinKCohen-SolalAFilippatosG. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J2008; 29: 2388–2442.
35.
PencinaMJD’AgostinoRBSrD’AgostinoRBJr. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med2008; 27: 157–172.
36.
NdrepepaGBraunSSchulzS. Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. Eur J Clin Invest2011; 41: 1054–1062.
37.
Bibbins-DomingoKGuptaRNaB. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA2007; 297: 169–176.
